Op-ed challenges GOP's psychedelic push without social supports

By AI, Created 10:35 AM UTC, May 20, 2026, /AGP/ – Two addiction and mental health experts argue in a STAT News op-ed that Republican support for ibogaine and other psychedelics clashes with cuts to housing, healthcare and community services. The piece says psychedelics can help only if they arrive with the social infrastructure needed for lasting recovery.

Why it matters: - The op-ed argues that psychedelics cannot deliver durable recovery if policymakers cut the housing, healthcare and community supports patients need after treatment. - The critique lands as Republicans promote ibogaine and other psychedelics for veterans and people with addiction while backing budget reductions that weaken the recovery system. - The authors say the debate is not just about access to a drug. It is about whether treatment is paired with the conditions that make it work.

What happened: - Ross Ellenhorn, a sociologist, psychotherapist and founder and CEO of Ellenhorn, and Dimitri Mugianis, a harm reduction advocate and psychedelic practitioner, published a STAT News op-ed on April 30, 2026. - The piece is titled “The Contradiction at the Heart of Republicans’ Embrace of Psychedelics.” - The authors challenge the GOP’s support for psychedelics days after President Trump signed an executive order intended to expand access to psychedelics for mental health treatment, with podcaster Joe Rogan at his side. - The op-ed specifically points to Republicans including Rick Perry, Greg Abbott, Dan Crenshaw and Morgan Luttrell as supporters of ibogaine and other psychedelics. - Ellenhorn and Mugianis say those lawmakers are also backing cuts that remove the infrastructure recovery depends on.

The details: - The authors argue that the strongest predictors of sustained recovery are social support, stable housing, employment, access to healthcare and community belonging. - They describe those factors as “recovery capital.” - The op-ed says even promising psychedelic treatments cannot take root when those supports are stripped away. - The authors warn that a focus on molecules, protocols and neurological mechanisms can obscure the relational and social conditions that make healing possible. - They argue that framing psychedelics as a chemical solution makes the movement easier to co-opt politically, because policymakers can celebrate a compound without rebuilding communities or funding long-term care. - Ellenhorn and Mugianis say psychedelics deserve better than being used to support a political project that dismantles the systems they rely on. - The piece includes the line: “You cannot detox a veteran with ibogaine and then send him back into housing insecurity, understaffed mental health systems, and shrinking social support. That is not innovation. It is abandonment wrapped in the language of breakthrough medicine.” - The authors also write: “If psychedelics are to enter American medicine responsibly,” they must arrive with “housing. Healthcare. Community mental health systems. Long-term therapeutic relationships. Economic stability.” - Ellenhorn and Mugianis are the co-founders of Cardea, an initiative that aims to integrate psychedelic-assisted approaches with the social and relational infrastructure tied to recovery.

Between the lines: - The op-ed is a warning to the psychedelic movement as much as to Republican policymakers. - Ellenhorn and Mugianis are not rejecting psychedelic medicine. They are arguing that the field becomes hollow if it treats the drug as the main intervention and ignores the social environment around the patient. - Their case reframes the politics of psychedelics from culture-war symbolism to public investment.

What’s next: - Ellenhorn and Mugianis are positioning Cardea as a model for combining psychedelic-assisted care with housing, community support and long-term treatment relationships. - The broader fight over psychedelics in American medicine is likely to keep centering on whether access expands alongside the social systems that make recovery last.

The bottom line: - Psychedelics may win political momentum, but the op-ed argues they will fail patients if lawmakers do not fund the recovery infrastructure around them.